echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Focus on ankylosing spondylitis, starting with "early detection" on World Spine Day

    Focus on ankylosing spondylitis, starting with "early detection" on World Spine Day

    • Last Update: 2023-01-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Yimaitong edited and sorted, please do not reprint
    without authorization.


    Recently, ankylosing spondylitis was suddenly hung up on the "hot search", because Li Yuchun revealed in a show that he had ankylosing spondylitis
    .
    After preliminary investigation, the prevalence of ankylosing spondylitis in China is not high, about 0.
    3%1, but considering the population base in China, the patient group is actually huge
    .
    World Spine Day, celebrated every year on 16 October, is a day to get to know the disease, its manifestations, diagnosis and treatment
    .


    Ankylosing spondylitis tends to occur in young adults


    Ankylosing spondylitis is a chronic inflammatory disease that mainly affects the sacroiliac joint, spine, paraspinal soft tissues and peripheral joints, and severe cases can cause spinal deformity and rigidity, and the late stage of spinal involvement may cause "bamboo-like changes" due to bone hyperplasia.

    The disease is more likely to occur in young people, the age of onset is 15~40 years old, 10%~20% of patients develop before the age of 16, the peak age of onset is 18~35 years old, and the onset of patients over 50 years old and under 8 years old is rare1
    .


    Ankylosing spondylitis is genetically related


    The cause of ankylosing spondylitis is unknown, but genetic and environmental factors are thought to play an important role in the onset of the disease1
    .
    Ankylosing spondylitis has been shown to have a clear familial tendency to aggregate and is strongly associated with
    positive human leukocyte antigen (HLA)-B27 gene.
    Patients who are HLA-B27 positive should be highly concerned about the possibility of inheriting the disorder in their children2
    .
    However, it should be noted that although ankylosing spondylitis is genetically related, the combination of intrinsic susceptibility genes and external factors (environmental factors, etc.
    ) in the pathogenic process will cause the disease
    .


    Understand the manifestations of ankylosing spondylitis and strive for early detection


    Ankylosing spondylitis has an insidious onset, and patients generally gradually develop low back or sacroiliac pain and/or stiffness, may wake up in the middle of the night, difficulty turning over, and lower back stiffness is obvious when rising in the morning or standing up after sitting for a long time, but it decreases
    after activity.
    Some patients have dull hip pain or severe lumbosacral pain that occasionally radiates
    to the periphery.
    The pain can worsen
    when coughing, sneezing, and suddenly twisting the lower back.
    Early hip pain is intermittent on one side or alternating between left and right
    .
    Most patients develop from the lumbar spine to the thoracic and cervical vertebrae, with pain, limited mobility, or spinal deformities1
    .


    Low back pain is an extremely common symptom in the general population, but most are mechanical back pain (herniated discs, lumbar muscle strain), while ankylosing spondylitis is an inflammatory back pain1
    .
    This is also the most dominant and characteristic clinical manifestation of ankylosing spondylitis, and is an important clue for early diagnosis3
    .
    The diagnostic criteria for inflammatory low back pain are: (1) age of onset< 40 years old; Chronic low back pain lasting more than 3 months; (3) Hidden onset; (4) morning stiffness; (5) Improve after activity, not relieve after rest; (6) Night pain<b14>.
    In addition, radiological sacroiliitis remains essential for diagnosis, so early imaging is key
    to early diagnosis of ankylosing spondylitis.


    Ankylosing spondylitis requires comprehensive treatment


    The treatment of ankylosing spondylitis includes a combination of non-drug and drug treatment, which, if diagnosed and treated appropriately, can control symptoms and improve prognosis
    .
    However, there is currently no cure for the disease1
    .


    Non-pharmacological treatments


    Exercise is the cornerstone of the treatment of ankylosing spondylitis, regardless of the type of exercise, moderate exercise can effectively reduce pain, improve motor function, enhance cardiopulmonary function and improve quality of life
    .
    Patients with ankylosing spondylitis should try to keep the chest straight, tummy and eyes level ahead when standing in life, sitting should keep the chest upright, sleep on a slightly harder mattress, take the supine position, and avoid promoting the posture of flexion deformity
    .
    The pillow should be short, and if thoracic or cervical spine involvement occurs
    , the pillow should be removed.
    In addition, smoking has been identified as one of the major environmental risk factors for several rheumatic diseases, and smoking cessation in patients with ankylosing spondylitis can help improve functional outcomes
    .


    drug therapy


    NSAIDs are the treatment of choice for ankylosing spondylitis2 and rapidly improve low back pain and morning stiffness, reduce joint swelling and pain, and increase range of motion1
    .
    If symptoms are not satisfied with the two-week relief using the maximum dose of NSAIDs, you can switch to another drug
    of the same class.
    If both NSAIDs are tried separately and neither of them controls symptoms, switching to a different class of drug, such as a biologic agent
    , is recommended.


    Biologic agents should be considered in patients who remain active despite NSAIDs, including tumor necrosis factor (TNF) α inhibitors and interleukin-17 inhibitors such as etanercept, infliximab, adalimumab, and sekukizumab
    .
    Methotrexate, leflunomide, sulfasalazine and other traditional synthetic antirheumatic drugs for the treatment of axial lesions of ankylosing spondylitis, the efficacy of which is unknown
    .
    If there is no way to get a more effective treatment, you can try it
    .


    Surgical treatment


    Surgery may be considered in patients with ankylosing spondylitis who do not respond effectively after adequate medical therapy, and functional limitations or joint deformities seriously affect quality of life
    .


    Early diagnosis according to the early clinical manifestations of patients can be intervened early, which is conducive to alleviating clinical symptoms, delaying disease progression, and improving quality of life
    .
    With the increase of new drugs, the treatment of ankylosing spondylitis is more abundant, and the overall prognosis of patients is gradually improving
    under timely, effective and standardized treatment.


    References:

    1.
    HUANG F, ZHU Jian, WANG Yuhua, et al.
    Diagnostic and therapeutic norms of ankylosing spondylitis[J].
    Chinese Journal of Internal Medicine,2022,61(8):893-900.
    DOI:10.
    3760/cma.
    j.
    cn112138-20211226-00913.

    2.
    XIE Ya, YANG Kehu, LV Qing, et al.
    Practice guidelines for patients with ankylosing spondylitis/spondyloarthritis[J].
    Chinese Journal of Internal Medicine,2020,59(7):511-518.
    DOI:10.
    3760/cma.
    j.
    cn112138-20200505-00448.

    3.
    ZHAO Zheng, HUANG Feng.
    Early and accurate diagnosis strategy of ankylosing spondylitis[J].
    Chinese Journal of Internal Medicine,2020,59(7):559-562.
    DOI:10.
    3760/cma.
    j.
    cn112138-20200509-00464.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.